Specify a stock or a cryptocurrency in the search bar to get a summary
Moberg Pharma AB (publ)
MOBMoberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden. Address: GustavslundsvAegen 42, Bromma, Sweden, 167 51
Analytics
WallStreet Target Price
209.23 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MOB
Dividend Analytics MOB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MOB
Stock Valuation MOB
Financials MOB
Results | 2019 | Dynamics |